About us

Company Overview

As of March 31, 2023

Company name Perseus Proteomics Inc.
Established Feb. 1, 2001
President & CEO Takuya Yokokawa
Head office

3F, A.i.Nihombashi EAST, 30-1 Nihonbashi Hakozakicho, Chuo-ku, Tokyo 103-0015, JAPAN

Google Map

Nagoya Laboratory

302 / 303 / 306 / 314, NALIC, 2-22-8 Chikusa, Chikusa-ku, Nagoya, Aichi 464-0858, JAPAN
*Visit us in Room No. 314.

Google Map

Capital 1,939 million yen
URL https://www.ppmx.com/en/
Listing market Growth Market, Tokyo Stock Exchange
Securities code 4882
Fiscal year April 1 to March 31
Business Drug discovery (development of antibody drugs), antibody research support, antibody and reagent sales
See here for details.
Employees 24
Board members See here for details.
Audit corporation KPMG AZUSA LLC

Company History

February 2001 Perseus Proteomics is established in Bunkyo-ku, Tokyo.
October 2002 A number of anti-nuclear receptor monoclonal antibodies are released as research reagents.
April 2003 The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by the New Energy and Industrial Technology Development Organization (NEDO) of the Ministry of Economy, Trade and Industry.
July 2003 The company relocates head office to Shibuya-ku, Tokyo.
August 2004 The company signs a distributorship agreement with R&D Systems Inc. for the distribution of its research reagents in the United States and initiates global sales.
September 2004 The company relocates head office to Meguro-ku, Tokyo.
September 2005 The complete lineup of antibodies that target all 48 nuclear receptors is presented.
September 2006 The company signs an agreement with Chugai Pharmaceutical Co., Ltd. for the transfer of right for the therapeutic use of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001).”
September 2008 The research reagent “PTX3 ELISA kit” is released.
November 2008 A phase I clinical trial of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001)” begins in the United States.
January 2009 Through shareholder allocation, FUJIFILM Corporation increases its capital in Perseus Proteomics by acquiring 76.68% of the issued shares to become the parent company.
January 2011 A radioisotope (RI)-labeled antibody (PPMX-T002), an anticancer drug, is licensed to FUJIFILM Corporation.
December 2014 A drug for the treatment of adult T-cell leukemia based on an anti-transferrin receptor antibody (PPMX-T003) is selected by the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) program of the Japan Science and Technology Agency (JST) for the practical application development (drug development) division.
September 2015 Antibody Drug Conjugate (PPMX-T004) is licensed to FUJIFILM Corporation.
January 2016 A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in the United States.
March 2018 After allocation of new shares to a third party, FUJIFILM Corporation reduces its percentage of shares of the Company to 48.62% and becomes an "other associated company".
January 2019 The company opens the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, for the maintenance and development of phage display technologies and the promotion of research and development of antibody drugs.
November 2019 A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) as an anticancer drug begins in Japan.
April 2020 A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in Japan.
June 2021 Shares of the Company are listed on Mothers Market, TSE
March 2022 Research and development on ANKL (PPMX-T003) is adopted as AMED Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation.
March 2022 License Agreement for PPMX-T002 and License & Knowhow Agreement for PPMX-T004 between FUJIFILM are terminated.
April 2022 The listed market transitions from Mother Market to Growth Market, TSE due to market segmentation restructuring of TSE.
September 2022 FUJIFILM Corporation is no longer "other associated company" due to reduction of its percentage of shares of the Company to 16.48%.
March 2023 Clinical Trial Notification of Investigator-led Phase I/II Clinical Trial for ANKL is submitted and approved.(PPMX-T003)
July 2023 The company relocates head office to Chuo-ku, Tokyo.

Origin of Company Name

「“Perseus” is a name of a Greek myth hero while “Proteomics” means research on structures and functions of protein.
Perseus, the hero, is said to have slayed Medusa, a monster who turned everyone who looked at her to stone and have saved Princess Andromeda from a sea monster. This company name represents our mission to fight with diseases (monsters) using antibody technology (Perseus’ weapons) to save patients (Andromeda).